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An impaired mechanism of regulatory feedback by matrix metalloproteinases (MMPs)
and tissue inhibitors of metalloproteinases (TIMPs) has been implicated in the develop-
ment of abdominal aortic aneurysms (AAAs).  This study examined the pathogenesis of
AAAs with respect to pathological characteristics and expressions of MMP-2, MMP-9
and TIMP-1.  Their expressions were evaluated by immunohistochemistry, competitive
polymerase chain reaction (PCR) and Western blotting in a total of 23 consecutive
AAAs.  The AAA specimens were obtained by surgery, while control specimens were ob-
tained at autopsy.  Specimens consisted of 6 patients with small-diameter AAAs (30–45
mm), 17 with medium-large-diameter AAAs (> 45 mm) and 11 controls (17–25 mm).
Immunohistochemistry showed MMP-2- and TIMP-1-positive cells mainly in the intima,
and MMP-9-positive cells in the intima and adventitia.  Competitive PCR showed a
significantly higher expression of MMP-2 messenger RNA (mRNA) in the small-diameter
AAAs, and higher expressions of MMP-9 mRNA in the small-diameter and medium-
large-diameter AAAs than in the controls.  The mRNA levels significantly correlated
between TIMP-1 and MMP-9, and between MMP-2 and MMP-9 in the AAAs, especially
in the medium-large-diameter AAAs.  Western blotting revealed the expression of MMPs
and TIMP-1 variably in all the specimens examined.  These results indicated that MMP-
2 and MMP-9 might act cooperatively and play a crucial role in the development of
AAAs, and that TIMP-1 inhibits MMP-9 in the AAAs, especially in those medium-
large-diameter AAAs.
Key words:  abdominal aortic aneurysm; competitive polymerase chain reaction; immuno-
histochemistry; matrix metalloproteinase; tissue inhibitor of metalloproteinase
Abbreviations:  AAA, abdominal aortic aneurysm; cDNA, complementary DNA ESDNA, external standard
DNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase;mRNA,
messenger RNA; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; SAB, streptavidin-biotin-
peroxidase; SCDNA, specimen cDNA;TIMP, tissue inhibitor of metalloproteinase
The pathologic hallmark of aortic aneurysm is
considered to be the remodeling of the aortic
wall, involving fragmentation and decrease of
elastic fibers in the tunica media (Baxter et al.,
1992; Gandhi et al., 1994).  True aneurysms
formed in Marfan’s syndrome (Chikumi et al.,
2000) were found to be due to a mutation in the
fibrillin gene (Dietz et al., 1991; Tsipouras et
al., 1992), indicating that aneurysms may be
caused by genetic disorders affecting 2 or more
components of the aortic wall.  Recent hypo-
theses have indicated that matrix metallo-
proteinases (MMPs) involved in the metabo-
lism of elastin in the wall of aortic aneurysms
may be one of the etiologic factors in the de-
velopment of abdominal aortic aneurysm
(AAA) (Campa et al., 1987; Tilson et al., 1988;
Baxter et al., 1992; Freestone et al., 1995;
Newman et al., 1994; Thompson et al., 1995;
McMillan et al., 1995, 1995, 1997; Tamarina et
al., 1997; Davis et al., 1998; Elmore et al., 1998).
However, the precise roles of monocytes, macro-
phages and vascular smooth muscle cells which
are considered to be involved in the early changes
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of vascular remodeling, have not been ade-
quately elucidated.  It is important to examine
the entire wall as a functioning organ using
molecular-biological techniques, to compare
the pathological changes of the individual
layers including the intima, tunica media and
adventitia.  AAAs might result from impair-
ment of the mechanism of regulatory feedback
by MMPs and tissue inhibitors of metallo-
proteinases (TIMPs).  A comparative analysis
of anatomic changes and tissue metabolism in
AAAs small in diameter without obvious struc-
tural destruction may provide a clue to the patho-
genesis.
With this background, the present study
examined the metabolism of elastin in the hu-
man aortic wall during the process of expansion
of aortic diameter with respect to the expression
of MMP-2, MMP-9 and TIMP-1.
Materials and Methods
Specimens
The subjects in this study consisted of 23 con-
secutive patients with AAA who had undergone
an elective excision with graft replacement be-
tween November 1998 and December 1999.
Eleven specimens obtained at autopsy perform-
ed between February 1999 and March 2000
served as controls.  Table 1 lists clinicopatho-
logical profiles of the AAA patients and the
autopsy cases.
Measurement of aortic diameter and stag-
ing of AAA
During surgery, the maximal diameter of the
aorta distal to the renal artery was measured di-
rectly using the divider.  The aortic diameter in
the control group was measured at autopsy.  In
this study, an aorta with a diameter more than
30 mm was defined as an AAA.  An aorta with a
diameter between 30 mm and 45 mm was de-
fined as a small-diameter AAA, and that with a
diameter over 45 mm as a medium-large-
diameter AAA.
Method for collection of aortic wall
After approval by the Ethics Committee of
Tottori University Faculty of Medicine, surgi-
cal specimens of the aortic wall were collected
from the patients after obtaining informed con-
sent.  During surgery, a rectangular strip of the
anterior wall was resected from the site of max-
imal diameter to the aneurysmal-normal junc-
tion throughout the wall.  At autopsy, a section
was obtained from the abdominal aorta with a
grossly atheroma-free intima throughout the
wall.  Immediately after resection, part of each
specimen was fixed in 10% neutral buffered
formalin for 48 h, and the rest was frozen in
liquid nitrogen and stored at –80˚C.
Histopathologic analysis
Three-micron-thick sections were cut from
paraffin-embedded human AAA walls and ab-
dominal aortas from autopsy materials.  The
sections were stained with hematoxylin-eosin
staining and elastica van Gieson.  For the local-
ization of MMP-2, MMP-9 and TIMP-1, the
streptavidin-biotin-peroxidase complex (SAB)
method was used for immunohistochemical
staining.  As the first antibody, purified mouse
monoclonal anti-human MMP-2 antibody
(diluted 1:200), purified mouse monoclonal
anti-human MMP-9 antibody (diluted 1:400),
purified mouse monoclonal anti-human TIMP-
1 antibody (diluted 1:200) (Fuji Chemical Inc.,
Takaoka, Japan), and purified mouse mono-
clonal anti-human HAM56 antibody (DAKO,
Carpenteria, CA) were used.  As the 2nd anti-
body and enzyme reagents, a Histofine SAB-
PO kit (Nichirei, Tokyo, Japan) was used.  En-
dogenous peroxidase activity was blocked with
methanol containing 0.3% hydrogen peroxide
at room temperature for 30 min.  For the retriev-
al of the antigens, all slides were placed in 10
mmol/L citrate buffer (pH 6.0) and heated at
94˚C for 15 min in a microwave oven.  Non-
specific staining was prevented by treatment
with phosphate-buffered saline (PBS) contain-
ing 2% fetal calf serum.  The sections were
treated with diaminobezidine for color develop-
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ment, and counterstained with 3% methyl
green.  The degree of tissue staining was judged
under a light microscope at 4 × 3.3 magnifica-
tion for elastica van Gieson staining and at 20 ×
5 magnification for immunohistochemical
staining, and then the expression was analyzed.
Competitive polymerase chain reaction
(PCR)
The frozen tissue samples were homogenized in
guanidium isothiocyanate using a Polytron
homogenizer (Kinematica, Luzern, Switzerland).
After homogenization, total RNA was isolated
by CsCl in ultracentrifugation at 100,000 g for
20 h.  Total RNA was further treated with gribo-
nuclease-free deoxyribonuclease I (Nippon
gene, Tokyo) and extracted with phenol/chloro-
form/isoamylalcohol (50:49:1) and precipitated
with ethanol.  Reverse transcription of 1.5-µg
total RNA was performed to synthesize com-
plementary DNA (cDNA) using 2 µL of 500-
µg/mL Random Hexamer (Promega, Madison,
WI) and 2 µL of 200-units/µL Moloney murine
leukemia virus reverse transcriptase (Gibco
BRL Products, Life Technologies, Rockville,
MD).  Control reactions omitting the reverse
transcriptase (reverse transcriptase negative)
were set up for each RNA sample.
The primers of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), MMP-2,
MMP-9 and TIMP-1 were designed based on
Tamarina’s report (Tamarina et al., 1997) by
using the Genetyx-Mac Macintosh software
(Software Development Co., Ltd., Tokyo)
(Table 2).  We designed the external standard
DNA (ESDNA) for each studied gene that
lacked from 10 to 20 base pairs (bp) so that the
ESDNA differed in size from the specimen
cDNA (SCDNA) obtained by the previous
method (Ho et al., 1989).  The identity of the
SCDNA and ESDNA was verified by DNA se-
quence analysis with ABI310 (Applied Bio-
systems, Tokyo).
The PCR reaction mixture (12 µL final vol-
ume) contained 0.64 µL of each cDNA, 0.5
Table 1.  Patient Characteristics
     Variable AAA Small Medium-large Control P value
AAA† AAA‡
Number of patients
   Total       23         6       17       11
   Male       22         5       17         7
   Female         1         1         0         4
Age                         (year)
   Mean ± SD 72.4 ± 6.8 70.3 ± 3.7 73.1 ± 7.8 66.1 ± 14.1 NS
   Range    62–85     66–77     62–85     47–92
Diameter                  (mm)
   Mean ± SD 53.3 ± 10.8 40.8 ± 5.6 57.5 ± 8.6 20.4 ± 2.4 < 0.01
   Range     30–80     30–45     48–80     17–25
History of smoking 16 (69.6)   5 (83.3) 11 (64.7)   7 (63.6) NS
Chronic obstructive
   pulmonary disease   8 (34.8)   1 (16.7)   7 (41.1)   1 (  9.1) NS
Hypertension 14 (60.9)   4 (66.7) 10 (58.8)   2 (18.2) NS
Diabetes mellitus   5 (21.7)   2 (33.3)   4 (23.5)   2 (18.2) NS
Hyperlipidemia   6 (26.1)   2 (33.3)   4 (23.5)   2 (18.2) NS
Ischemic heart disease 10 (43.5)   1 (16.7)   9 (52.9)   0 (  0   ) < 0.01
Arteriosclerosis obliterans   7 (30.4)   2 (22.2)   5 (29.4)   1 (  9.1) NS
Cerebrovbascular disease   3 (13.0)   1 (16.7)   2 (11.8)   3 (27.3) NS
Malignant tumor   5 (21.7)   3 (50.0)   2 (11.8)   8 (72.7) < 0.05
(   ), %.
AAA, abdominal aorataic aneurysm; NS, not significant.
† Aneurysmal diameter, 30–45 mm.
‡ Aneurysmal diameter, > 45 mm.
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units Taq polymerase (Gene Amp Taq Gold,
Perkin Elmer, Branchburg, NJ), 12 pmol of for-
ward primer, 6 pmol of reverse primer conju-
gated with Cy5 (Amersham Pharmacia Biotech,
Buckinghamshire, England) and 6 pmol of re-
verse primer.  For each sample, 4 or 5 equal
aliquots were prepared with a dilution series of
the ESDNA, and the PCR mixture was spiked
into these aliquots.  Amplification was perform-
ed in the thermal cycler (Labosystems Japan
Co., Tokyo) for 35 cycles:  denaturation at 95˚C
for 1 min; annealing for 1 min at 55˚C for
GAPDH, MMP-9 and TIMP-1 and at 60˚C for
MMP-2; and extension at 72˚C for 1 min.
As the reverse primer was fluorescently
labeled with Cy5, PCR products were detected
with an ALF red DNA Sequencer (Amersham
Pharmacia Biotech).  After competitive PCR
was completed, the products corresponding to
the SCDNA and the ESDNA were electro-
phoresed on a 6% polyacrylamide and 6 mol/L
urea gel on the Sequencer.  The peaks were
detected and analyzed with the Allele Links
software (Amersham Pharmacia Biotech).  The
specific SCDNA template in each starting
cDNA sample was equimolar to ESDNA when
that ESDNA area/SCDNA area was equal to 1
(Fig. 1).  The RNA amount is presented as a
percentage to glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH).
Western blotting
Frozen specimens of human AAA walls or
autopsied abdominal aortic walls were homo-
genized in a homogenizer, and the homogenate
was dissolved in lysis buffer containing 0.1%
nonylphenoxy polyethoxy ethanol (NP-40).
The solution was centrifuged in an ultracentri-
fuge at 15,000 revolutions per minute for 10 min,
and the supernatant was used as a test sample.
The concentration of protein was measured
with a Protein Assay Kit (Bio-Rad, Hercules,
CA).  Test samples of the same protein content
(375 µg) were electrophoresed on a 5% sodium
dodecyl-sulfate-polyacrylamide gel at a con-
stant voltage of 150 V, and the proteins were
transferred onto a nitrocellulose membrane at
80 V for 150 min.  Markers (Bio-Rad Labs.,
Richmond, CA) were dissolved in a Coomassie
brilliant blue solution and used for electro-
phoresis.  After blocking nonspecific reaction
with 10% skim milk in PBS, the membrane was
reacted at 4˚C overnight with one of the follow-
ing first antibodies: purified mouse monoclonal
anti-human MMP-2 antibody (diluted 1:50),
Table 2.  Primers used for competitive PCR
Gene PCR Length (bp) Primer
MMP-2 SP 398 5’=CAGGCTCTTCTCCTTTCACAAC
3’=AAGCCACGGCTTGGTTTTCCTC
ESP 379 5’=ACTCCAGACCCCTGGCTTTT
3’=CCAGGGGTCTGGAGTTGTCCCACTGCCCTGTGCCA
MMP-9 SP 172 5’=TGGGCTACGTGACCTATGACAT
3’=GCCCAGCCCACCTCCACTCCTC
ESP 162 5’=AAGGAGCCAGTTTGCCGGAT
3’=GCAAACTGGCTCCTTGGTCCCAGTGGGGATTTACA
TIMP-1 SP 279 5’=GGGGCTTCACCAAGACCTACAC
3’=AAGAAAGATGGGAGTGGGAACA
ESP 267 5’=TCTGAAAAGGGCTTCCAGTC
3’=GAAGCCCTTTTCAGACTGGTCCGTCCACAAGCAAT
GAPDH SP 216 5’=TGCCTCCTGCACCACCAACTGC
3’=ATGACCTTGCCCACAGCCTT
ESP 205 5’=TGGAAGGACTCATGACCACA
3’=TCATGAGTCCTTCCATTGTCATGGATGACCTTGGC
bp, base pair; ESP, external standard primer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP,
matrix metalloproteinase; PCR, polymerase chain reaction; SP, specimen primer; TIMP, tissue inhibitor of
metalloproteinase.
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purified mouse monoclonal anti-human MMP-
9 (diluted 1:50) and purified mouse monoclonal
anti-human TIMP-1 (diluted 1:50) (Fuji Chemi-
cal Inc., Takaoka).  Subsequently, the mem-
brane was reacted with purified goat polyclonal
peroxidase-conjugated anti-mouse immuno-
globulin G antibody (diluted 1:1,000) as the 2nd
antibody at room temperature for 1 h.  The
membrane was washed with PBS, and treated
with enhanced chemiluminescence Western
blotting solution.  The enhanced chemilumines-
cence of protein bands was detected by expos-
ing X-ray film to the membrane, and the expres-
sion of MMP-2, MMP-9 and TIMP-1 proteins
was evaluated.
Statistical analysis
Using the StatView (Abacus Concepts, Inc.,
Berkeley, CA) software, the difference between
2 groups was tested by the Mann-Whitney U
test.  Differences among multiple groups were
tested by the Kruskal-Wallis test, and the
groups with significant differences were tested
by the Tukey test (nonparametric test).  The
correlation between 2 groups was tested with
Spearman’s correlation coefficient by rank.  A
value of P < 0.05 was considered significant.
Results
Staging of AAA
The 23 patients with AAA (≥ 30 mm) consisted
of 22 men and 1 woman.  The mean age (± SD)
was 72.4 ± 6.8 years, and the mean diameter (±
SD) of aneurysms was 53.3 ± 10.8 mm.  Of
them, 6 patients (5 males and 1 female) had
small AAAs (30–45 mm):  their mean age was
70.3 ± 3.7 years and the mean diameter of aneu-
rysms, 40.8 ± 5.6 mm (small-diameter AAA
group).  The remaining 17 patients (all male)
had medium or large AAAs (> 45 mm):  their
mean age was 73.1 ± 7.8 years and the mean
diameter of aneurysms, 57.5 ± 8.6 mm (medium-
large-diameter AAA group).
The control group of 11 autopsy cases con-
sisted of 7 males and 4 females aged 66.1 ± 14.1
years:  the mean aortic diameter was 20.4 ± 2.4
mm.  There were no significant differences
among the 3 groups in clinicopathological pro-
files, except for aortic diameter, history of is-
chemic heart disease and malignant disease
(Table 1).
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Fig. 1.  A: Polymerase chain reaction (PCR) products were detected with an ALF red DNA Sequencer
(Amersham Pharmacia Biotech), as the reverse primer was fluorescently labeled with Cy5.  The Peaks were
detected and analyzed with the Allele Links software (Amersham Pharmacia Biotech).  B: The specific
specimen cDNA (SCDNA) template in each starting cDNA sample was equimolar to the external standard
DNA (ESDNA) when that ESDNA area/SCDNA area was equal to 1.
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Fig. 2.  Tissue sections taken from a small-diameter
abdominal aortic aneurysm (AAA) (a), a medium-
large AAA (b) and an autopsy case (c) were stained
with elastica van Gieson.  The degree of the staining
was judged under a light microscope at an original
magnification of 4 × 3.3.
Histopathologic findings
Medial elastic fibers in AAA walls were
markedly fragmented or lost in the aortic wall
of the aneurysms examined.  The walls of
medium-large-diameter AAAs showed marked
thickening of the adventitia compared with the
walls of small-diameter AAAs (Figs. 2a and b).
In contrast, medial elastic fibers were preserved
in the aortic walls of the autopsy cases (Fig. 2c).
Immunohistochemistry revealed that intra-
cytoplasmic cells positive for MMP-2, MMP-9
and TIMP-1 were noted in macrophages and
lymphocytes as well as vascular smooth muscle
cells.  MMP-2-positive cells were present in the
intimal plaques and thickened intimas in the
AAA walls (Fig. 3a).  MMP-9-positive cells
were present in the outer layer of the tunica
media, adventitia and intimal plaques in the
AAA walls (Fig. 3b).  TIMP-1-positive cells
were noted in the intimal plaques (Fig. 3c).
HAM56-positive cells were seen in similar lo-
cations to MMP-9-positive cells in the AAA
walls (Fig. 3d).  A few cells positive for MMP-
2, MMP-9 and TIMP-1 were also demonstrated
in the control aortic walls.
Competitive PCR
Of the 34 specimens, messenger RNA (mRNA)
could be obtained from 10 controls, 6 small
AAAs and 14 medium-large AAAs.  Figure 4
shows the expression ratios of MMP-2, MMP-9
and TIMP-1 to the internal control GAPDH.
Table 3 summarizes the mean expression ratios
of MMP-2, MMP-9 and TIMP-1 in the 3
groups.  The MMP-2 expression ratio was the
highest in the small AAAs, the value being
significantly higher than that of the 10 controls
(P < 0.05).  The MMP-9 expression ratio was
higher in the small AAAs and the medium-large
a
b
c
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Fig. 3.  AAA tissue shows a positive immunoreaction for matrix metalloproteinase (MMP)-2 (a), MMP-9 (b),
tissue inhibitor of metalloproteinase (TIMP)-1 (c) and HAM56 (d).  The degree of immunohistochemical
staining was judged under a light microscope at an original magnification of 20 × 5.
AAAs than in the control group, P values being
less than 0.01 and 0.05, respectively.  On the
other hand, there was no significant difference
among the 3 groups on the TIMP-1 expression
ratio, although the expression ratio tended to be
higher in the small AAAs.  Overall, the highest
expression was noted in MMP-2, followed by
TIMP-1 and MMP-9, in the order given.
The medium-large AAAs were divided into
2 subgroups by diameter; medium type < 65
mm and large type ≥ 65 mm.  The mean expres-
sion ratio of MMP-9 was 0.026 ± 0.051 in the
medium-type AAA [n = 11] and 0.006 ± 0.009
in the large-type AAA [n = 3], the value being
higher in the former than in the latter without
significant differences.  The mean expression
ratios of MMP-2 and TIMP-1 were 0.045 ±
0.073 and 0.334 ± 0.521 in the medium type and
0.281 ± 0.419 and 0.128 ± 0.190 in the large
type, respectively.  There was no statistical
difference.
Table 4 shows the results of Spearman’s
coefficient by rank to examine the relationship
of the expressions among MMP-2, MMP-9 and
TIMP-1.  The expression levels of MMP-9 and
TIMP-1 signficantly correlated in all the AAAs
and the medium-large AAAs (P < 0.01, Fig. 5),
but not in the small AAAs and controls.
Moreover, the expression levels of MMP-2 and
MMP-9 also significantly correlated in a similar
fashion (P < 0.05, Table 4).  No significant
correlation of expression was noted between
MMP-2 and TIMP-1.
Western blotting
Protein could be obtained from a total of 9
specimens, 3 each from the 3 groups.  MMP-2,
MMP-9 and TIMP-1 were variably expressed
as shown in Fig. 6.  Of these, an obviously
higher expression of MMP-2 and TIMP-1 was
a c
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noted in 2 of the small AAAs.  A higher expres-
sion of MMP-2 was also noted in 1 of the 3
aneurysms of the control group.  On the other
hand, MMP-9 showed lower or almost no ex-
pressions in all the specimens examined.
Discussion
This study analyzed the relationship between
the development of AAAs and the expression of
MMP-2, MMP-9 and TIMP-1 in the aortic
walls.  The AAAs were subclassified into 2
categories due to the diameter of AAAs; small
type being 45 mm or less, and medium-large
type being greater than 45 mm.  This classifica-
tion is based on a previous observation, which
confirmed that AAAs with diameters greater
than 45 mm showed a higher frequency of aneu-
rysmal rupture (Kanaoka et al., 1999).  Maeda
et al. (1996) described 3 stages of AAA pro-
gression; development, growth and rupture.
They corrected the diameter of AAAs followed
by body height as a congenital factor and by age
as an acquired factor, and found that small and
medium-large AAAs corresponded well to the
stages of growth and rupture, respectively.
The present study confirmed the highest
expression of MMP-2 mRNA as well as protein
levels among the 3 molecules.  The expression
was significantly higher in the small-diameter
AAAs than in the controls, suggesting the in-
volvement of MMP-2 in the growth of AAAs.
This is partially consistent with the report by
Freestone et al. (1995), who found that the
production of MMP-2 protein was higher in the
AAAs of 40 to 55 mm in diameter.  Moreover, it
is well known that MMP-2 is expressed only in
small amounts in obstructive arteriosclerotic
lesions (Freestone et al., 1995; Davis et al.,
1998).  Thus, it is conceivable that MMP-2
might play a crucial role in the development and
growth, i.e., an early stage of AAAs.
Fig. 4.  Scatter diagrams show the expressions of matrix metalloproteinase (MMP)-
2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 mRNA in small
abdominal aortic aneurysms (AAAs) [ n = 6] and medium-large AAAs [n = 14] and
in control specimens [n = 10].  The RNA amount is presented as a percentage to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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Table 3.  mRNA expressions of MMP-2, MMP-9 and TIMP-1 in the small and medium-large
AAAs and controls
MMP-2 MMP-9 TIMP-1
Controls [10] 0.02 ± 0.03       
*
0.001 ± 0.002     
*
   ** 0.01 ± 0.03
Small AAAs [  6] 3.17 ± 6.04 0.03   ± 0.03 0.58 ± 0.98
Medium-large AAAs [14] 0.10 ± 0.20 0.02   ± 0.05 0.29 ± 0.47
[  ], number of specimens
AAA, abnormal arotic aneurysm; MMP, matrix metalloproteinase; mRNA, messenger RNA; TIMP, tissue
inhibitor of metalloproteinase.
*P < 0.05; **P < 0.01.
Both small and medium-large AAAs show-
ed higher expressions of MMP-9 than controls.
When the medium-large AAAs were divided
into 2 subgroups by size, the mean expression
ratio of MMP-9 mRNA was higher in the
medium-type AAAs than in the large-type
AAAs, although the difference was not sig-
nificant.  Similar results were reported by
McMillan et al. (1997), who divided AAAs into
3 groups; small (less than 49 mm), medium
Table 4.  Correlation of MMP-2, MMP-9 and TIMP in the small, medium-large and total AAAs
and controls
Small AAA Medium-large AAA AAA Controls
MMP-2 and MMP-9 –0.20 [6] 0.62 [15]* 0.46 [21]* 0.06 [10]
MMP-2 and TIMP-1 0.26 [6] 0.42 [14] 0.30 [20] 0.39 [10]
MMP-9 and TIMP-1 0.77 [6] 0.75 [15]** 0.70 [21]** 0.52 [11]
[  ], number of specimens
AAA, abnormal arotic aneurysm; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metallo-
proteinase.
Spearman’s correlation coefficient by rank (*P < 0.05, **P < 0.01).
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Fig. 5.  Correlations between matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase
(TIMP)-1.  There is a significant correlation between TIMP-1 and MMP-9 in AAAs [n = 21, r = 0.70, P <
0.01] (left), especially in medium-large AAAs [n = 15, r = 0.75, P < 0.01] (right).  The RNA amount is
presented as a percentage to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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(50–69 mm) and large (more than 70 mm).
They found a significantly higher expression in
the medium type than in the small or large type.
In other words, the MMP-9 expression obvious-
ly decreased in the large AAAs.  Moreover, im-
munohistochemistry confirmed a diffuse dis-
tribution of MMP-9-positive cells in the entire
aneurysmal wall, in contrast to mainly intimal
localization of MMP-2- and TIMP-1-positive
cells.  In spite of the expression ratio of MMP-9
being lower than that of MMP-2, the results
indicated that MMP-9 might influence the dis-
order of elastin metabolism and participate in
the growth stage of AAAs, as suggested by
McMillan et al. (1997).
It is of interest that the MMP-2 and MMP-9
expressions well correlated in the medium-
large AAAs, but not in the small AAAs.  The
simultaneous lower expressions of MMP-2 and
MMP-9 could imply that the gene expression
might be regulated by the aneurysmal stroma or
the cell-stromal interaction in the remodeled
aneurysmal wall.
TIMP-1 has been shown to inhibit the activ-
ity of MMPs and to prevent the degeneration of
elastic fibers, as well as development and rup-
ture of AAAs (Birkedal-Hansen et al., 1993;
Allaire et al., 1998).  In the present study, the
TIMP-1 expression significantly correlated
with MMP-9 in the medium-large AAAs, sug-
gesting that TIMP-1 might inhibit MMP-9 in a
reactive or protective manner.  In fact, there was
no significant correlation between the ex-
pressions of TIMP-1 and MMP-9 in the small
AAAs and control specimens.  Although there
was no statistical correlation between the ex-
pressions of TIMP-1 and MMP-2, there was a
tendency for the TIMP-1 expression to increase
along with the MMP-2 expression.
In conclusion, this study demonstrated that
MMP-2 and MMP-9 play crucial roles in the
development or growth of AAAs, and that
TIMP-1 inhibits their proteinase activity.  The
precise roles of other MMP and TIMP family
molecules, such as TIMP-2, await further clarif-
ication.
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